160
2024-04-08 07:09:48
In The Lancet the results of 2 phase III studies into the effectiveness and safety of ligelizumab in patients have been published ≥ 12 years with chronic spontaneous urticaria (CSU). Ligelizumab was more effective than placebo, but not than omalizumab. The safety profile of ligelizumab was consistent with that in previous studies.
More information is only accessible to subscribers who are authorized to prescribe.
Login
NB: To view all information you need an account to log in. Are you already logged in? Then you do not have sufficient rights to view this information. Do you want to adjust your account? Then click here
#Ligelizumab #adults #adolescents #chronic #spontaneous #urticaria